SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-18-238228
Filing Date
2018-08-03
Accepted
2018-08-03 16:01:05
Documents
5
Period of Report
2018-07-31
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d600304d8k.htm 8-K 25960
2 EX-10.1 d600304dex101.htm EX-10.1 44280
3 EX-99.1 d600304dex991.htm EX-99.1 14179
4 GRAPHIC g600304g0801224348198.jpg GRAPHIC 3354
5 GRAPHIC g600304g0801224821070.jpg GRAPHIC 4748
  Complete submission text file 0001193125-18-238228.txt   97366
Mailing Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472
Business Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472 617-926-5000
EyePoint Pharmaceuticals, Inc. (Filer) CIK: 0001314102 (see all company filings)

IRS No.: 262774444 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 000-51122 | Film No.: 18991774
SIC: 3826 Laboratory Analytical Instruments
Assistant Director 10